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Minimization cost analysis of hospitalization of 40 patients
affected by hemopoietic malignancies that underwent autol-
ogous bone marrow transplantation has been performed.
Clinical records of 27 patients treated with Filgrastim have
been compared with records of 13 patients not treated. The
retrospective comparative analysis included days of hospi-
talization, antibiotic therapy, nursing time, transfusion epi-
sodes, microbiological cultures required. Overall average
hospitalization cost since transplantation for treated patients
was £65,537,774 versus £69,479,878 (p  0.004). Average
hospitalization time since transplantation for treated pa-
tients was 29.3 days versus 32.7 for not treated. Thus, hos-
pitalization after transplantation was 3.4 days (HR 5.3;
95% C.I. 2.0 to 13.9) shorter for treated, accounting for a
10.4% saving in hospitalization time. Treated patients had
average 5.6 days less in sterile room (HR 5.0; 95% C.I. 2.0
to 12.4). Every treated patient hospitalization raised savings
for at least £3.942.104, taking into account the average sav-
ings in hospitalization days after transplantation. Moreover,
Filgrastim use lead to overall and “sterile” nursing timesav-
ings of 6.5% and 16.8%, results in accordance with shorter
hospitalization. Our results are similar to those reported by
other studies. Suitable use of Filgrastim, reducing hospital-
ization length and disease course, appears to be a valid way
to improve health-care efficiency.
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Douillard et al. (1999), have reported a multicenter, ran-
domized, controlled open label study comparing irinote-
can (Campto®) in combination with 5-fluorouracil (5-
FU) and folinic acid (FA) therapy with fluorouracil/FA
alone as first line treatment for metastatic colorectal can-
cer. They concluded that irinotecan in combination with
5-FU offered consistent significant advantages in terms of
efficacy and clinical benefit over single agent 5-FU with-
out any detrimental effects upon quality of life. We aim
to relate these data to relevant costs within the UK and to
evaluate the economic implications of the difference in
survival between the two treatment arms from the view-
point of a UK NHS commissioner. This work develops
the second line assessment of irinotecan by Iveson et al.
(1999) in the EJC, which concluded that irinotecan
achieved results of £14,000 per life year saved in the sec-
ond line setting. This cost-effectiveness analysis compares
the economic implications of replacing 5-FU therapy as a
single agent (de Gramont regimen or AIO regimen) plus
folinic acid rescue with irinotecan in combination with
5-FU/FA (de Gramont regimen, or AIO regimen). Drug ac-
quisition costs are derived from the British National For-
mulary (March 1999); unit costs for clinical consultations
and services are derived from relevant 1997/1998 cost
databases. Costs associated with treatment delivery and
disease complications are also considered. Indirect costs
although important are not included, in line with the
viewpoint of commissioners within the NHS. Although
cumulative drug acquisition costs per patient are higher
with irinotecan and 5-FU/FA than with infusional 5-FU/
FA therapy alone, these costs are at least partially offset
by lower cumulative costs per patient associated with
treatment of complications in the irinotecan plus 5-FU/
FA arm than in the 5-FU/FA alone arm.
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OBJECTIVE: Lung cancer is a major cause of death in the
UK and small cell lung cancer (SCLC) represents about
20% of primary lung tumors. The costs associated with the
management of SCLC are significant, however few studies
have been conducted in the UK to determine their true ex-
tent. The aim of this study was to obtain an estimate of the
current patterns of treatment and associated resource use
and costs for SCLC in the UK.
METHODS: Study sites were two hospitals in Newcastle-
upon-Tyne. A focus group meeting with local clinicians
clarified the expected pathways of SCLC care. Forms for
retrospective patient record data extraction were developed
on a per treatment phase basis. Data was collected on a
consecutive series of 106 patients diagnosed with SCLC be-
tween 1994 and 1997. Unit costs were determined from lo-
cal hospital accounts and secondary sources.
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RESULTS: Per treatment phase average costs and associ-
ated percentages for the first 56 patients were: referral
and diagnosis £1,964 (11.21%); active therapy £6,147
(35.09%); follow-up £1,103 (6.30%); retreatment(s) £3,804
(21.72%); subsequent follow-up(s) £560 (3.20%) and ter-
minal care £3,937 (22.47%). The high cost of active ther-
apy was primarily due to the long inpatient stays associated
with chemotherapy. Similarly, the high cost of terminal
care was predominantly due to hospitalizations and/or hos-
pice stays. The total average cost of treatment pre-recur-
rence exceeded that of post-recurrence (52.6% of costs vs.
47.4%).
CONCLUSION: The results of this analysis show that the
average costs of treating SCLC are considerable, although
the variability between patients in terms of the type and
quantity of resource use was very high. Such analyses pro-
vide a useful insight into resources used in actual clinical
practice. This study has identified the major cost drivers
and when combined with outcome data will form the basis
of future economic evaluations of SCLC treatments.
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OBJECTIVES: To translate the QOL-RTI H&N for use
with German patients. The Quality of Life-Radiation
Therapy Instrument Head & Neck (QOL-RTI) is a multi-
dimensional psychometric instrument designed specifically
to assess health related quality of life (QoL) in patients un-
dergoing radiation therapy. The head and neck module
(H&N) is a companion module to the QOL-RTI for head
and neck patients. This instrument differs from other ex-
isting tools such as the EORTC H&N or the FACT H&N
by including more specific aspects of saliva, taste, swal-
lowing, and local pain in a concise format.
METHODS: Healthcare professionals from Austria and
Germany translated and linguistically validated the instru-
ment. The current literature reports that translation of ex-
isting health status measures is best accomplished with the
double-back translation method. This method was used to
assure the accurate translation of the tool. It was deter-
mined that there is no exact match for some words or
phrases, so appropriate translations were derived.
RESULTS: Specific difficulties encountered in the transla-
tion were determining cultural nuances or slang in the
source document. For example, question number 7 in En-
glish says I worry about my bills and in the German trans-
lation it now says I worry about my financial situation. It
was determined that these and several other questions may
have different literal meanings in English and German, so
words were changed to ensure the same intent (implied
meanings) as the original questionnaire.
CONCLUSIONS: It is necessary to take great care when
translating existing health care measures from one lan-
guage into another so that the translated version will have
content and semantic equivalence across the cultures rep-
resented in the project. Psychometric testing is currently
being conducted. In addition to German, the QOL-RTI
H&N has been translated into Japanese, Italian, Greek
and Spanish and is in various stages of validation and test-
ing in these languages.
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OBJECTIVE: The suggested approach (models and the da-
tabase) enables one to evaluate changes in disease-specific
health care utilization and associated costs which could re-
sult from a health care intervention, including the introduc-
tion of new medicines in various therapeutic areas.
METHODS: Disease-specific estimates of health care utili-
zation and associated medical expenses distributed by types
of care and sources of payment have been constructed by
applying a linear model with exogenous population weights
and normalizing coefficients to relational data files derived
from the National Medical Expenditure Survey data. A
proportional attributable risk model, which incorporates
exogenous parameters accounting for causality, inflation,
discounting, human costs associated with lost earnings, and
population structural changes, has been developed for esti-
mating direct and indirect costs of diseases. These con-
structed cost estimates (direct, direct by types of care and
indirect) have been used as input variables for benefit-cost
and cost-effectiveness models.
RESULTS: Health care utilization profiles have been con-
structed for lung cancer, non-small cell lung cancer
(NSCLC), and NSCLC in stage III-IV. For a regimen in-
cluding a new drug in addition to Taxol and Carboplatin,
which will add at least 97 days to a median survival, to be
cost saving, it has to reduce the individual disease cost by
28.3%. For the same regimen to enable a system cost sav-
ing it has to ensure 34.6% changes in a system health care
cost. This new product will be cost-effective at the thresh-
old of $80,000 per life year gained if it is priced within
$8,000–$13,700. Within this price range, the estimated in-
dividual averted cost might reach $7,000–$17,000.
CONCLUSIONS: The suggested approach allows one to
link clinical efficacy to plausible changes in health out-
comes, health care utilization and attendant costs at any of
the levels and types of health care delivery.
